Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma
ConclusionWe provide the data showing that PEG-LD 50 mg/m2 combined with cisplatin 100 mg/m2 demonstrated an acceptable safety profile and promising clinical activity in advanced osteosarcoma, which merits further evaluation in phase II studies.Trial registrationChiCTR1900021550.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Anemia | Arrhythmia | Bone Cancers | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Hematology | Osteosarcoma | Study | Thrombocytopenia | Toxicology